CEBPZ and acute myeloid leukemia: In our CBF-AML patients not receiving allogeneic HSCT in CR1, the poor long-term LFS of only 20–30% (Supplementary Figure S5) was comparable with the results from an earlier report on t(8;21) AML from our center28 and other reports from Asia,29, 30 but inferior to results reported from larger international studies.31, 32 It is unclear whether the inferior results of chemotherapy in our patients were because of a different gene mutation spectrum, the small size of this cohort or a difference in treatment regimens.